TY - JOUR
T1 - Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device
AU - Ferrero, Simone
AU - Tramalloni, Daniela
AU - Venturini, Pier Luigi
AU - Remorgida, Valentino
PY - 2011/5
Y1 - 2011/5
N2 - Objective: To evaluate the effectiveness of treatment with vaginal danazol in improving the pain symptoms caused by rectovaginal endometriosis that persist after insertion of a levonorgestrel-releasing intrauterine device (LNG-IUD). Methods: This pilot observational study included 15 women with rectovaginal endometriosis and pain symptoms persisting after LNG-IUD insertion. Vaginal danazol (100 mg per day) was self-administered for 6 months. The intensity of pain symptoms and the volume of rectovaginal endometriotic nodules were evaluated. Results: Twelve women were satisfied or very satisfied with the treatment. After treatment with vaginal danazol for 3 months, there was a significant decrease in the intensity of pain symptoms compared with their intensity before the administration of danazol. The intensity of pain symptoms decreased further at 6-month follow-up. The volume of the rectovaginal nodules decreased after treatment with vaginal danazol for 6 months (1.7 ± 0.8 cm3) compared with the baseline volume (2.3 ± 0.9 cm 3; P <0.001). Adverse effects of the treatment were minimal and well tolerated. Conclusion: Although a placebo effect cannot be excluded, the results indicate that vaginal danazol decreases the severity of endometriosis-related pain symptoms after LNG-IUD insertion.
AB - Objective: To evaluate the effectiveness of treatment with vaginal danazol in improving the pain symptoms caused by rectovaginal endometriosis that persist after insertion of a levonorgestrel-releasing intrauterine device (LNG-IUD). Methods: This pilot observational study included 15 women with rectovaginal endometriosis and pain symptoms persisting after LNG-IUD insertion. Vaginal danazol (100 mg per day) was self-administered for 6 months. The intensity of pain symptoms and the volume of rectovaginal endometriotic nodules were evaluated. Results: Twelve women were satisfied or very satisfied with the treatment. After treatment with vaginal danazol for 3 months, there was a significant decrease in the intensity of pain symptoms compared with their intensity before the administration of danazol. The intensity of pain symptoms decreased further at 6-month follow-up. The volume of the rectovaginal nodules decreased after treatment with vaginal danazol for 6 months (1.7 ± 0.8 cm3) compared with the baseline volume (2.3 ± 0.9 cm 3; P <0.001). Adverse effects of the treatment were minimal and well tolerated. Conclusion: Although a placebo effect cannot be excluded, the results indicate that vaginal danazol decreases the severity of endometriosis-related pain symptoms after LNG-IUD insertion.
KW - Danazol
KW - Endometriosis
KW - Intrauterine device
KW - Levonorgestrel
KW - Rectovaginal endometriosis
UR - http://www.scopus.com/inward/record.url?scp=79953805276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953805276&partnerID=8YFLogxK
U2 - 10.1016/j.ijgo.2010.11.015
DO - 10.1016/j.ijgo.2010.11.015
M3 - Article
C2 - 21333989
AN - SCOPUS:79953805276
VL - 113
SP - 116
EP - 119
JO - International Journal of Gynecology and Obstetrics
JF - International Journal of Gynecology and Obstetrics
SN - 0020-7292
IS - 2
ER -